Related Experiment Video
Updated: May 31, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Pleural mesothelioma side populations have a precursor phenotype
Claudia Frei1, Isabelle Opitz, Alex Soltermann
1Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital Zürich, Haeldeliweg 4, 8044 Zurich, Switzerland.
Malignant pleural mesothelioma (MPM) side population (SP) cells exhibit chemoresistance and self-renewal, potentially driving tumor recurrence after chemotherapy. Targeting these SP cells may offer new therapeutic strategies for MPM.
Area of Science:
- Oncology
- Cancer Biology
- Cell Biology
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
- Tumor recurrence after chemotherapy suggests the presence of chemoresistant cancer stem cells.
- Identifying these resistant subpopulations is crucial for developing effective therapies.
Purpose of the Study:
- To identify chemoresistant subpopulations within MPM using a side population (SP) functional assay.
- To investigate the self-renewal, chemoresistance, and tumorigenicity of SP versus non-side population (NSP) cells.
- To characterize the phenotype of SP cells and their potential role in tumor recurrence.
Main Methods:
- DyeCycleViolet staining to establish the SP assay for identifying chemoresistant MPM cells.
- Assays for self-renewal, chemoresistance, and tumorigenicity in SP and NSP fractions.
- Immunohistochemical characterization of tumors (mesothelin, calretinin, N-cadherin, D2-40, WT1) and flow cytometry for stem cell markers (CD90, CD73, CD105).
Main Results:
- SP cells in MPM demonstrated self-renewal properties and enhanced chemoresistance compared to NSP cells.
- Tumors derived from SP cells showed a mesothelium precursor phenotype (WT1 negative, cytoplasmic D2-40 positive) and increased tumorigenicity.
- SP cells were enriched for CD105 negative/low expression, smaller size, and higher tumorigenicity, mirroring phenotypic shifts in relapsed tumors post-chemotherapy.
Conclusions:
- Chemoresistant, small-sized, CD105 negative/low SP cells in MPM are implicated as the cellular source of tumor recurrence.
- These SP cells possess self-renewal and chemoresistance capabilities, suggesting they function as cancer stem cells.
- Further research into the mechanisms of chemoresistance and self-renewal in this subpopulation could identify novel therapeutic targets for MPM.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Cellular Adaptation IV: Dysplasia and Metaplasia
Abnormal Proliferation
Cancers Originate from Somatic Mutations in a Single Cell
Pleura of the Lungs

